ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Interest Income

Income earned on cash, deposits, and investments held by the company.

ProQR Therapeutics N.V.NASDAQ: PRQR

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of €215.49K fell 52.6% year over year, ahead of the -60.2% change in trailing-twelve-month interest income. Sequentially, it rose 82.8% from the prior quarter. Over 3 fiscal years it compounded at +176.5% a year.

Context

  • Interest income amounted to 14.7% of revenue in FY2025, down 2.5 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -52.6% holds above the trailing-twelve-month pace of -60.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€215.49K+82.8% QoQ
Last fiscal yearDec 2025
€2.24M-31.1% YoY
LTMMar 2026
€852.58K-60.2% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-52.6%——
1 year-31.1%——
3-year CAGR+176.5%——
5-year CAGR——
10-year CAGR——

Interest Income history

EUR · from the income statement

Latest · FY2025
2.24M EUR
Year-over-year change
-31.1%
4-year CAGR
+360.1%

Interest Income vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -60.2% is the 9th highest of 10, against a peer median of -32.7%.
  • Interest income amounts to 6.3% of revenue for PRQR, versus a peer median of 62.3%.
PRQR Competitors
Interest Income for PRQR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$17.35M USD-14.3%+61.7%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$13.26M USD-32.7%—231.0%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$9.27M USD-47.9%+57.6%20.4%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$8.43M USD+242.7%+128.9%—
ZURAZura Bio LimitedLTM Mar 2026$5.84M USD-32.1%+2131.8%—
IMMPImmutep LimitedFY2025A$5.25M AUD+35.2%+186.0%104.1%
MREOMereo BioPharma Group plcLTM Mar 2026$1.84M USD-40.4%+46.2%367.5%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$1.47M USD-36.4%+95.9%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€852.58K EUR-60.2%+176.5%6.3%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$0 USD——0.0%
EDITEditas Medicine, Inc.LTM Mar 2026-$1.51M USD-112.9%+14.6%3.9%
Peer median (excluding PRQR) —-32.7%+78.8%62.3%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.34M3.59M6.51M18.91M15.28M
Cost of Revenue00002.6M
Gross Profit1.34M3.59M6.51M18.91M12.68M
Gross Margin100.0%100.0%100.0%100.0%83.0%
Research & Development42.22M50.87M25.15M36.36M40.72M
Selling, General & Admin17.37M18.65M16.24M13.66M14.12M
Operating Expenses58.55M68.75M38.37M49.38M54.84M
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
EBITDA(54.95M)(56.46M)(24.1M)(24.12M)(37.04M)
EBITDA Margin-4116.0%-1571.0%-369.9%-127.6%-242.4%
Operating Income(57.21M)(65.16M)(31.86M)(30.47M)(42.15M)
Operating Margin-4285.4%-1813.0%-489.1%-161.2%-275.9%
Interest Income5K106K2.59M3.25M2.24M
Interest Expense3.41M5.13M1.2M1.08M866.4K
Other Income / Expenses(3.47M)1.05M4.05M2.51M1.65M
Income Before Tax(60.68M)(64.11M)(27.81M)(27.96M)(40.5M)
Pre-Tax Margin-4545.5%-1783.8%-427.0%-147.9%-265.1%
Income Tax Expense117K96K(78K)(197K)18.25K
Net Income(60.74M)(64.42M)(28.12M)(27.76M)(40.52M)
Net Margin-4549.8%-1792.5%-431.7%-146.9%-265.2%
EPS (Basic)(0.96)(0.91)(0.35)(0.34)(0.38)
EPS (Diluted)(0.96)(0.91)(0.35)(0.34)(0.38)
Weighted Avg Shares64.18M71.64M81.01M81.67M105.33M
Weighted Avg Shares (Diluted)64.18M71.64M81.01M81.67M105.33M

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.